



## Vertex to Present at the Credit Suisse Healthcare Conference on November 12

November 7, 2019

BOSTON--(BUSINESS WIRE)--Nov. 7, 2019-- [Vertex Pharmaceuticals Incorporated](#) (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET.

Management's remarks will be available live through Vertex's website at [www.vrtx.com](http://www.vrtx.com) in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

### About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on *Science* magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit [www.vrtx.com](http://www.vrtx.com) or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191107005925/en/>

Source: Vertex Pharmaceuticals Incorporated

### Vertex Investor Contacts:

Michael Partridge, 617-341-6108

Zach Barber, 617-341-6470

Leah Gibson, 617-961-1507